Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.
Julio Garcia-AguilarSujata PatilMarc J GollubJin K KimJonathan Benjamin YuvalHannah M ThompsonFloris S VerheijDana M OmerMeghan LeeRichard F DunneJorge E MarcetPeter CataldoBlasé N PoliteDaniel O HerzigDavid LiskaSamuel OommenCharles M FrielCharles A TernentAndrew L CovelerSteven HuntAnita GregoryMadhulika G VarmaBrian L BelloJoseph C CarmichaelJohn C KraussAna L GleisnerPhilip B PatyMartin R WeiserGarrett M NashEmmanouil PappouJosé G GuillemLarissa TempleIris H WeiMaria WidmarSabrina T LinNeil H SegalAndrea CercekRona YaegerJ Joshua SmithKaryn A GoodmanAbraham Jing-Ching WuLeonard B SaltzPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Organ preservation is achievable in half of the patients with rectal cancer treated with total neoadjuvant therapy, without an apparent detriment in survival, compared with historical controls treated with chemoradiotherapy, TME, and postoperative chemotherapy.